Orexo´s Nomination Committee for the Annual General Meeting 2025

Group 1 - The Nomination Committee for Orexo's Annual General Meeting (AGM) on May 8, 2025, has been appointed, consisting of four members [1] - The Nomination Committee represents approximately 34 percent of the voting power in Orexo as of August 31, 2024 [1] - Proposals from the Nomination Committee will include recommendations for the Chairman of the meeting, Board members, and remuneration details [1][2] Group 2 - Orexo is a Swedish pharmaceutical company with nearly 30 years of experience in developing pharmaceuticals, particularly for opioid use disorder [3] - Total net sales for Orexo in 2023 amounted to SEK 639 million, with a workforce of 116 employees [3] - Orexo is listed on Nasdaq Stockholm and is available as an ADR on OTCQX in the US [3]